Risks To Shareholder Returns Are Elevated At These Prices For NEUCA S.A. (WSE:NEU)
Jul 19
Polish (WIG) Healthcare Sector Analysis
UpdatedJul 26, 2024
DataAggregated Company Financials
Companies48
- 7D0.3%
- 3M3.0%
- 1Y6.2%
- YTD3.6%
Last week, the Healthcare industry hasn't moved much but Celon Pharma is up 14% in that time. As for the the longer term, the industry is up 6.2% over the past 12 months. As for the next few years, earnings are expected to grow by 27% per annum.
Sector Valuation and Performance
Has the Polish Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Jul 2024 | zł14.9b | zł16.2b | zł133.8m | 31.2x | 111.7x | 0.9x |
| Sun, 23 Jun 2024 | zł14.6b | zł16.2b | zł102.5m | 26.2x | 142x | 0.9x |
| Tue, 21 May 2024 | zł15.2b | zł16.0b | zł80.3m | 23.6x | 189.6x | 1x |
| Thu, 18 Apr 2024 | zł14.7b | zł16.0b | -zł100,002,749.00 | 38.9x | -147.4x | 0.9x |
| Sat, 16 Mar 2024 | zł15.2b | zł16.0b | -zł218,743,549.00 | 40.8x | -69.6x | 1x |
| Mon, 12 Feb 2024 | zł14.6b | zł15.9b | -zł257,176,129.00 | 36.5x | -56.7x | 0.9x |
| Wed, 10 Jan 2024 | zł14.9b | zł15.9b | -zł245,263,080.00 | 32.2x | -60.9x | 0.9x |
| Fri, 08 Dec 2023 | zł14.4b | zł15.9b | zł94.7m | 29.5x | 151.8x | 0.9x |
| Sun, 05 Nov 2023 | zł13.4b | zł15.7b | zł110.2m | 31.1x | 121.4x | 0.9x |
| Tue, 03 Oct 2023 | zł13.5b | zł15.7b | zł114.7m | 27.3x | 117.5x | 0.9x |
| Thu, 31 Aug 2023 | zł14.2b | zł15.5b | zł103.2m | 23.3x | 137.5x | 0.9x |
| Sat, 29 Jul 2023 | zł14.4b | zł15.4b | zł101.1m | 24.9x | 142x | 0.9x |
| Mon, 26 Jun 2023 | zł14.5b | zł15.4b | zł123.0m | 26.5x | 117.6x | 0.9x |
| Wed, 24 May 2023 | zł14.2b | zł15.4b | zł192.5m | 26.1x | 73.6x | 0.9x |
| Fri, 21 Apr 2023 | zł13.3b | zł15.5b | zł256.1m | 27.1x | 52x | 0.9x |
| Sun, 19 Mar 2023 | zł13.5b | zł15.1b | zł259.2m | 26.9x | 52.1x | 0.9x |
| Tue, 14 Feb 2023 | zł13.2b | zł15.0b | zł233.2m | 31.2x | 56.7x | 0.9x |
| Thu, 12 Jan 2023 | zł13.5b | zł15.0b | zł237.9m | 26x | 56.9x | 0.9x |
| Sat, 10 Dec 2022 | zł12.6b | zł15.0b | zł229.8m | 26.9x | 54.9x | 0.8x |
| Mon, 07 Nov 2022 | zł12.1b | zł14.8b | -zł136,902,320.00 | 19.7x | -88.2x | 0.8x |
| Wed, 05 Oct 2022 | zł12.0b | zł14.8b | -zł117,425,044.00 | 24x | -102.1x | 0.8x |
| Fri, 02 Sep 2022 | zł12.2b | zł14.6b | zł259.2m | 20.3x | 47x | 0.8x |
| Sun, 31 Jul 2022 | zł12.6b | zł14.8b | zł265.8m | 20.8x | 47.5x | 0.9x |
| Tue, 28 Jun 2022 | zł11.7b | zł14.8b | zł265.8m | 17.6x | 43.9x | 0.8x |
| Thu, 26 May 2022 | zł116.9b | zł14.7b | zł270.5m | 22.8x | 432.2x | 8x |
| Sat, 23 Apr 2022 | zł14.7b | zł15.1b | zł843.1m | 24.1x | 17.4x | 1x |
| Mon, 21 Mar 2022 | zł14.9b | zł14.9b | zł900.7m | 23.3x | 16.6x | 1x |
| Wed, 16 Feb 2022 | zł15.4b | zł14.8b | zł920.2m | 27.1x | 16.8x | 1x |
| Fri, 14 Jan 2022 | zł17.6b | zł14.8b | zł930.7m | 25.3x | 18.9x | 1.2x |
| Sun, 12 Dec 2021 | zł16.9b | zł14.8b | zł929.1m | 24.1x | 18.2x | 1.1x |
| Tue, 09 Nov 2021 | zł18.1b | zł14.7b | zł1.3b | 32.3x | 13.9x | 1.2x |
| Thu, 07 Oct 2021 | zł17.4b | zł14.7b | zł1.3b | 30.3x | 13.3x | 1.2x |
| Sat, 04 Sep 2021 | zł18.7b | zł14.4b | zł1.4b | 31x | 13.1x | 1.3x |
| Mon, 02 Aug 2021 | zł18.7b | zł14.4b | zł1.4b | 29.8x | 13.2x | 1.3x |
Price to Earnings Ratio
13.2x
Current Industry PE
- Investors are optimistic on the Polish Healthcare industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 112x which is higher than its 3-year average PE of 34.6x.
- The industry is trading close to its 3-year average PS ratio of 0.96x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 55% per year over the last three years.
- Meanwhile revenues for these companies have grown 3.9% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Polish Healthcare sector?
| PL Market | -2.84% | |
| Healthcare | 0.31% | |
| Pharma | 7.58% | |
| Healthtech | 4.32% | |
| Life Sciences | 2.73% | |
| Medical Equipment | 2.15% | |
| Biotech | 0.11% | |
| Healthcare Services | -4.07% | |
Industry PE
- Investors are most optimistic about the Healthcare Services industry even though it's trading below its 3-year average PE ratio of 28.6x.
- Analysts are expecting annual earnings growth of 19.7%, which is lower than the prior year's growth of 89.7% per year.
Forecasted Growth
- Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 109% over the next 5 years.
- This is better than its past earnings growth rate of 25% per year.
- In contrast, the Life Sciences industry is expected to see its earnings growth to stay flat over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CLN Celon Pharma | zł29.45 | 9.5% +zł130.2m | 74.3% | PS7.2x | |
| SNT Synektik Spólka Akcyjna | zł144.80 | 5.7% +zł66.5m | 109.2% | PE16.2x | |
| PUR Pure Biologics | zł29.05 | 58.7% +zł35.8m | 77.1% | PS1401.1x | |
| NNG NanoGroup | zł3.93 | 57.2% +zł34.6m | 224.8% | PB29.8x | |
| ICE Medinice | zł12.40 | 47.6% +zł26.2m | -26.6% | PS360.6x |
